CKHUY - Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO

• Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market.
• Hutchmed expects to spend $300 million on R&D this year, up 72% from 2020, and is looking to further expand its capital market access to other stock exchange to give it more access to other funding sources.
• The targeted therapies and immunotherapies that are Hutchmed’s specialty have been growing fast for cancer treatments worldwide, with a combined market size of $125.8 billion last year.

For further details see: